Oculis (NASDAQ:OCS) Trading Up 8.3%

Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares traded up 8.3% during mid-day trading on Monday . The stock traded as high as $13.16 and last traded at $13.02. 82,027 shares changed hands during mid-day trading, an increase of 74% from the average session volume of 47,052 shares. The stock had previously closed at $12.02.

Analysts Set New Price Targets

OCS has been the subject of a number of research analyst reports. HC Wainwright lowered their price objective on shares of Oculis from $29.00 to $28.00 and set a "buy" rating for the company in a research report on Wednesday, April 24th. Robert W. Baird dropped their price objective on Oculis from $64.00 to $35.00 and set an "outperform" rating for the company in a research note on Tuesday, March 19th. Wedbush reissued an "outperform" rating and set a $29.00 target price on shares of Oculis in a research note on Wednesday, March 6th. Finally, Chardan Capital restated a "buy" rating and set a $30.00 target price on shares of Oculis in a report on Tuesday, March 19th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $29.14.

Oculis Price Performance

The firm has a 50 day moving average of $11.85 and a two-hundred day moving average of $11.24. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.29 and a current ratio of 5.29.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.04. The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.28 million. As a group, sell-side analysts anticipate that Oculis Holding AG will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Oculis

Several hedge funds have recently made changes to their positions in the business. Wolverine Asset Management LLC acquired a new stake in shares of Oculis during the third quarter worth $77,000. Searle & CO. purchased a new stake in shares of Oculis in the fourth quarter valued at about $112,000. Compagnie Lombard Odier SCmA increased its stake in shares of Oculis by 47.3% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 95,750 shares of the company's stock worth $1,053,000 after acquiring an additional 30,750 shares during the period. Finally, abrdn plc purchased a new position in Oculis during the fourth quarter worth about $15,980,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.